2025 China Antibodies In Oncology Market Revenue Opportunities Report
Description
The 2025 China Antibodies In Oncology Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibodies in Oncology Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the antibodies in oncology market in China are BeiGene, Innovent Biologics, Junshi Biosciences, and WuXi Biologics. BeiGene focuses on innovative cancer therapies, particularly antibody drugs, with collaborations with global pharmaceutical companies to expand its reach. Innovent Biologics is notable for its partnership with Roche to develop and commercialize a revolutionary antibody-drug conjugate (ADC) IBI3009 for small cell lung cancer. Junshi Biosciences specializes in cancer immunotherapy, advancing antibody drugs and cell therapies through clinical trials. WuXi Biologics offers end-to-end antibody development and manufacturing solutions with a robust global presence and advanced platforms like WuXiBody™, enabling complex multispecific antibodies, including ADCs.
These companies are leading the Chinese oncology antibody sector not only through innovative drug development but also by engaging in global collaborations and advanced manufacturing. WuXi Biologics, with one of the world’s largest biologics manufacturing capacities, supports large-scale antibody production. Innovent Biologics’ licensing deal with Roche underscores China’s increasing role in global oncology biotech innovation. Additionally, Junshi and BeiGene leverage diverse antibody modalities—such as monoclonal and bispecific antibodies—to target cancer, reflecting China's strategic emphasis on bridging biosimilar production with innovation-driven growth. Together, these firms enhance China’s competitive stance in the fast-growing global antibody market for cancer treatment.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibodies in Oncology Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the antibodies in oncology market in China are BeiGene, Innovent Biologics, Junshi Biosciences, and WuXi Biologics. BeiGene focuses on innovative cancer therapies, particularly antibody drugs, with collaborations with global pharmaceutical companies to expand its reach. Innovent Biologics is notable for its partnership with Roche to develop and commercialize a revolutionary antibody-drug conjugate (ADC) IBI3009 for small cell lung cancer. Junshi Biosciences specializes in cancer immunotherapy, advancing antibody drugs and cell therapies through clinical trials. WuXi Biologics offers end-to-end antibody development and manufacturing solutions with a robust global presence and advanced platforms like WuXiBody™, enabling complex multispecific antibodies, including ADCs.
These companies are leading the Chinese oncology antibody sector not only through innovative drug development but also by engaging in global collaborations and advanced manufacturing. WuXi Biologics, with one of the world’s largest biologics manufacturing capacities, supports large-scale antibody production. Innovent Biologics’ licensing deal with Roche underscores China’s increasing role in global oncology biotech innovation. Additionally, Junshi and BeiGene leverage diverse antibody modalities—such as monoclonal and bispecific antibodies—to target cancer, reflecting China's strategic emphasis on bridging biosimilar production with innovation-driven growth. Together, these firms enhance China’s competitive stance in the fast-growing global antibody market for cancer treatment.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
